Updated Guidance for Chronic Rhinosinusitis Follow-Up

Abstract

Chronic rhinosinusitis (CRS) represents a prevalent and multifactorial inflammatory condition of the paranasal sinuses, frequently encountered in otolaryngology and primary care settings. The clinical management and follow-up of CRS have evolved with recent advancements in diagnostic modalities, an improved understanding of pathophysiology, and updated guideline recommendations. This review synthesizes current evidence on the epidemiology, risk factors, mechanistic underpinnings, diagnostic strategies, therapeutic options, and practical implications for the longitudinal care of patients with CRS, with a particular focus on updated approaches to follow-up care in clinical practice.

Introduction

Chronic rhinosinusitis is defined as inflammation of the sinonasal mucosa persisting for 12 weeks or longer, despite attempts at medical management. CRS imposes a significant burden on patient quality of life and healthcare systems globally. Its management is complex, encompassing medical, surgical, and adjunctive therapies, and requires vigilant follow-up to monitor disease control, guide therapy modification, and prevent complications. Recent clinical guidelines have underscored the importance of individualized follow-up strategies tailored to disease phenotype and severity, necessitating ongoing updates for clinicians managing this challenging condition.

Epidemiology / Disease Burden

CRS affects an estimated 12-16% of the adult population in Western countries, with substantial variability by region, diagnostic criteria, and environmental exposures. The disease is responsible for millions of ambulatory visits annually and is associated with considerable direct and indirect costs due to absenteeism, decreased productivity, and diminished quality of life. Patients with CRS often report persistent nasal obstruction, facial pain or pressure, hyposmia, and fatigue, leading to a significant reduction in daily functioning. The chronicity and potential for recurrence underscore the importance of structured follow-up protocols to optimize long-term outcomes.

Pathophysiology

CRS is characterized by a complex interplay between host immune responses, environmental factors, and microbial colonization. Central to its pathogenesis is chronic inflammation of the sinonasal mucosa, mediated by type 1 (Th1), type 2 (Th2), or mixed immune responses, depending on the endotype. CRS with nasal polyps (CRSwNP) is typically associated with eosinophilic, Th2-skewed inflammation and elevated local IgE, whereas CRS without nasal polyps (CRSsNP) tends to reflect a neutrophilic, Th1-dominated pattern. Disruption of mucociliary clearance and loss of epithelial barrier integrity further perpetuate the cycle of inflammation and infection. These mechanisms inform both diagnostic approaches and emerging targeted therapies.

Risk Factors

Key risk factors for CRS include atopy, asthma, allergic rhinitis, immunodeficiency, exposure to air pollutants, tobacco smoke, and anatomical variations such as septal deviation or concha bullosa. Certain comorbidities, including cystic fibrosis and aspirin-exacerbated respiratory disease, are strongly associated with specific CRS phenotypes. Recurrent upper respiratory infections, occupational exposures, and genetic predisposition also contribute to disease development and persistence. Recognizing and addressing modifiable risk factors is crucial during follow-up to reduce recurrence and improve patient outcomes.

Clinical Features

The cardinal symptoms of CRS nasal obstruction, mucopurulent drainage, facial pain/pressure, and olfactory dysfunction must persist for at least 12 weeks for diagnosis. Additional features may include cough, fatigue, and dental pain. Physical examination may reveal nasal polyps, mucosal edema, or purulent secretions on anterior rhinoscopy or endoscopy. Disease severity and impact can be assessed using validated patient-reported outcome tools, such as the Sinonasal Outcome Test-22 (SNOT-22), which are instrumental in guiding follow-up and therapeutic decisions.

Diagnosis

The diagnosis of CRS is based on clinical criteria corroborated by objective evidence of sinonasal inflammation, typically via nasal endoscopy or computed tomography (CT) imaging. Endoscopic findings include mucosal edema, polyps, and purulent secretions, while CT provides detailed assessment of sinus opacification, mucosal thickening, and anatomical variations. Microbiological sampling may be considered in refractory cases or those with suspected atypical infection. Differential diagnosis includes acute rhinosinusitis, allergic rhinitis, and non-sinonasal causes of facial pain, necessitating a careful, systematic approach to evaluation and follow-up.

Treatment & Management

Initial management of CRS involves intranasal corticosteroids, saline irrigations, and, in select cases, short courses of systemic corticosteroids or antibiotics. Adjunctive therapies may include antihistamines, leukotriene antagonists, or immunotherapy for patients with allergic comorbidities. Surgical intervention, such as functional endoscopic sinus surgery (FESS), is indicated for patients with persistent symptoms despite optimized medical therapy or those with complications. Long-term management emphasizes symptom control, prevention of exacerbations, and surveillance for complications, highlighting the importance of structured follow-up visits to monitor response and adjust treatment accordingly.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advances in the understanding and treatment of CRS. Biologic therapies targeting key inflammatory mediators such as anti-IL-4/IL-13 (dupilumab), anti-IL-5 (mepolizumab, reslizumab), and anti-IgE (omalizumab) have demonstrated efficacy in patients with severe, refractory CRSwNP, reducing polyp size, symptom burden, and the need for revision surgery. Advances in endoscopic surgical techniques, image-guided navigation, and postoperative care protocols have improved patient outcomes and reduced perioperative risks. Ongoing research into sinonasal microbiome modulation and host-microbe interactions holds promise for future therapeutic strategies.

Guideline Recommendations

Updated international and national guidelines, including those from the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS 2020) and the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS), emphasize the importance of individualized, phenotype-driven management and follow-up. Key recommendations include: regular assessment of symptom control using validated tools; periodic endoscopic evaluation to monitor mucosal status; tailored imaging based on clinical suspicion; and early identification of treatment failures or complications. Multidisciplinary collaboration is encouraged, especially for patients with comorbid asthma, allergy, or immune dysfunction. Follow-up intervals should be adjusted according to disease activity, treatment response, and risk of recurrence, with clear pathways for escalation of care when needed.

Conclusion

Chronic rhinosinusitis is a complex, heterogeneous disease requiring a nuanced, evidence-based approach to follow-up and long-term management. Advances in understanding its pathophysiology, risk stratification, and therapeutic options have enabled more precise, individualized care. Ongoing clinician education, adherence to updated guideline recommendations, and the integration of emerging therapies into clinical practice are essential for optimizing patient outcomes and minimizing disease burden. Structured, patient-centered follow-up protocols remain central to effective CRS management in contemporary clinical settings.